Literature DB >> 26072072

Clinicopathological characteristics and prognosis of patients with adenosquamous lung carcinoma.

Ye Guo1, Lin Jia1, Guo-Guang Shao2, Hong-Wei Sun1, Xing-Xing Wang1, Guan-Jun Wang1, Ke-Wei Ma3.   

Abstract

This study was aimed to characterize clinicopathological features and prognosis of patients with adenosquamous lung carcinoma (ASC). Among the 2531 patients with lung cancer who underwent surgery between January 2000 and June 2012 in our hospital, 59 were histologically diagnosed as having ASC. The clinicopathological features and follow-up data of ASC patients were collected and analyzed statistically. Superior lobectomy was accomplished in 40 patients, middle and inferior lobectomy in 3, lobectomy plus partial resection of contralateral lung in 5, partial lung resection in 4, and pneumonectomy in 7. Moreover, 22 cases were found to be adenocarcinoma-predominant, and 18 to be squamous cell carcinoma-predominant. The median survival time was 13.6 months, and the 1-, 3-, and 5-year survival rates were 59.9%, 36.4% and 31.2%, respectively. Of the 52 cases with tissue specimens available, 11 had an EGFR mutation (21.2%) and 2 had a KRAS mutation (3.8%). Multivariate analysis showed that histology subtype, pleural invasion, TNM stage, and postoperative treatment were all independent prognostic factors. The data from the current study demonstrated that SCC-predominant histology represents a better prognosis of ASC. Histology subtype, pleural invasion, TNM stage, and postoperative treatment are independent prognostic factors for ASC and adjuvant therapy may help control the disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26072072     DOI: 10.1007/s11596-015-1436-z

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  32 in total

1.  Survival comparison of adenosquamous, squamous cell, and adenocarcinoma of the lung after lobectomy.

Authors:  David T Cooke; Danh V Nguyen; Ying Yang; Steven L Chen; Cindy Yu; Royce F Calhoun
Journal:  Ann Thorac Surg       Date:  2010-09       Impact factor: 4.330

2.  Adenosquamous carcinoma of the lung. Clinicopathologic and immunohistochemical features.

Authors:  T Ishida; S Kaneko; H Yokoyama; T Inoue; K Sugio; K Sugimachi
Journal:  Am J Clin Pathol       Date:  1992-05       Impact factor: 2.493

3.  Adenosquamous lung carcinomas: a histologic subtype with poor prognosis.

Authors:  Pier Luigi Filosso; Enrico Ruffini; Sofia Asioli; Roberto Giobbe; Luigia Macri; Maria Cristina Bruna; Alberto Sandri; Alberto Oliaro
Journal:  Lung Cancer       Date:  2011-03-02       Impact factor: 5.705

4.  EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung.

Authors:  Xiao-Li Jia; Gang Chen
Journal:  Lung Cancer       Date:  2011-05-17       Impact factor: 5.705

Review 5.  Are adenosquamous lung carcinomas a simple mix of adenocarcinomas and squamous cell carcinomas, or more complex at the molecular level?

Authors:  Kristell Bastide; Nicolas Ugolin; Céline Levalois; Jean-François Bernaudin; Sylvie Chevillard
Journal:  Lung Cancer       Date:  2009-12-08       Impact factor: 5.705

6.  A clinicopathologic study of the resected cases of adenosquamous carcinoma of the lung.

Authors:  M Kamiyoshihara; T Hirai; O Kawashima; S Ishikawa; Y Morishita; A Maeshima
Journal:  Oncol Rep       Date:  1998 Jul-Aug       Impact factor: 3.906

7.  Adenosquamous carcinoma of the lung: a clinical and pathologic study of seven cases.

Authors:  P L Fitzgibbons; W H Kern
Journal:  Hum Pathol       Date:  1985-05       Impact factor: 3.466

8.  Clinicopathological characteristics of EGFR mutated adenosquamous carcinoma of the lung.

Authors:  Toshihiro Shiozawa; Genichiro Ishii; Koichi Goto; Kanji Nagai; Sachiyo Mimaki; Shotaro Ono; Seiji Niho; Satoshi Fujii; Yuichiro Ohe; Katsuya Tsuchihara; Atsushi Ochiai
Journal:  Pathol Int       Date:  2013-02-21       Impact factor: 2.534

9.  Adenosquamous carcinoma of the lung: CT, FDG PET, and clinicopathologic findings.

Authors:  Youkyung Lee; Jin-Haeng Chung; Sang Eun Kim; Tae Jung Kim; Kyung Won Lee
Journal:  Clin Nucl Med       Date:  2014-02       Impact factor: 7.794

10.  Optimizing the management of advanced non-small-cell lung cancer: a personal view.

Authors:  M D Vincent
Journal:  Curr Oncol       Date:  2009-08       Impact factor: 3.677

View more
  4 in total

1.  Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.

Authors:  Haikuo Zhang; Christine Fillmore Brainson; Shohei Koyama; Amanda J Redig; Ting Chen; Shuai Li; Manav Gupta; Carolina Garcia-de-Alba; Margherita Paschini; Grit S Herter-Sprie; Gang Lu; Xin Zhang; Bryan P Marsh; Stephanie J Tuminello; Chunxiao Xu; Zhao Chen; Xiaoen Wang; Esra A Akbay; Mei Zheng; Sangeetha Palakurthi; Lynette M Sholl; Anil K Rustgi; David J Kwiatkowski; J Alan Diehl; Adam J Bass; Norman E Sharpless; Glenn Dranoff; Peter S Hammerman; Hongbin Ji; Nabeel Bardeesy; Dieter Saur; Hideo Watanabe; Carla F Kim; Kwok-Kin Wong
Journal:  Nat Commun       Date:  2017-04-07       Impact factor: 14.919

2.  Tumor Location and Survival Outcomes in Lung Adenosquamous Carcinoma: A Propensity Score Matched Analysis.

Authors:  Xinlin Shi; Xiangrong Shao; Yawen Zhang; Feng Wu; Yujian Tao
Journal:  Med Sci Monit       Date:  2020-07-02

Review 3.  Research progress of the clinicopathologic features of lung adenosquamous carcinoma.

Authors:  Jing Wang; Yanling Wang; Mengting Tong; Hongming Pan; Da Li
Journal:  Onco Targets Ther       Date:  2018-10-16       Impact factor: 4.147

4.  Predictive and prognostic value of preoperative serum tumor markers in resectable adenosqamous lung carcinoma.

Authors:  Qiongjie Zhi; Yuqian Wang; Xinyue Wang; Dongsheng Yue; Kai Li; Richeng Jiang
Journal:  Oncotarget       Date:  2016-10-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.